Allan Oberman - Dr Reddys Non-Executive Independent Director

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;padding-top: 25px;;'>DR</div>
RDY -- USA Stock  

USD 52.01  0.12  0.23%

  Director
Mr. Allan Oberman is NonExecutive Independent Director of the Company
Age: 61  Director Since 2019  MBA    
91 40 4900 2900  http://www.drreddys.com
Allan Oberman served as the Chief Executive Offi cer of Concordia International Corporationrationration from November 2016 until May 2018. In his career of more than 35 years he also served as CEO of Sagent Pharmaceuticals Inc., and President and CEO of Teva Americas Generics, a subsidiary of Teva Pharmaceutical Industries Limited. Prior to that, Mr. Oberman served as President of Teva EMIA, where from 2010 to 2012 he was responsible for Eastern Europe, Middle East, Israel and Africa. From 2008 to 2010, he served as the Chief Operating Offi cer of the Teva International Group, and from 2000 to 2008, he served as the President and CEO of Teva Canada . From 1996 to 2000, Mr. Oberman was the President of Best Foods Canada Inc. He holds directorship in Planet Shrimp Inc. and Jay Pharma Inc., both in Canada. He has an MBA from the Schulich School of Business, York University, Toronto and a BA from Western University, London.

Dr Reddys Management Efficiency

Dr Reddys Laboratories has Return on Asset of 8.02 % which means that on every $100 spent on asset it made $8.02 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 13.21 %, implying that it generated $13.21 on every 100 dollars invested. Dr Reddys management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.
The company has 811.73 M in debt with debt to equity (D/E) ratio of 0.14, which may show that the company is not taking advantage of profits from borrowing. Dr Reddys Laboratories has a current ratio of 1.75, which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

DIRECTOR Since

Thomas FreymanAllergan Plc
2018
Alfred GilmanRegeneron Pharmaceuticals
1990
Wyllie CornwellPfizer Inc
1997
Don CornwellPfizer Inc
1997
Dan LittmanPfizer Inc
2018
Theodore SamuelstoPerrigo Company Plc
2017
Louise ParentZoetis Inc
2013
Gregory NordenZoetis Inc
2013
Joseph GoldsteinRegeneron Pharmaceuticals
1991
Jacqualyn FousePerrigo Company Plc
2012
Carol DavidsonAllergan Plc
2018
Michael GreenbergAllergan Plc
2018
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Shlomo YanaiPerrigo Company Plc
N/A
Robert ScullyZoetis Inc
2013
Bradley AlfordPerrigo Company Plc
2017
Herman MorrisPerrigo Company Plc
1999
Jeffrey SmithPerrigo Company Plc
2017
Theodore SamuelsPerrigo Company Plc
2017
Paul BisaroZoetis Inc
2015
Nesli BasgozAllergan Plc
2014

Company Summary

Reddys Laboratories Limited operates as an integrated pharmaceutical company worldwide. The company was founded in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on BATS Exchange. It employs 21650 people.Dr Reddys Laboratories (RDY) is traded on BATS Exchange in USA and employs 21,650 people.

Dr Reddys Laboratories Leadership Team

G Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director
MARC KIKUCHI, Chief Executive Officer, North America Generics
Hans Hasler, Additional Independent Director
Leo Puri, Non-Executive Independent Director
Sandeep Poddar, Compliance Officer, Company Secretary
Satish Reddy, Co-Chairman of the Board
Kedar Upadhye, IR Contact Officer
Samiran Das, Executive Vice President Head - FTO and GGPM
Patrick Aghanian, Chief Executive Officer, European Generics
Sauri Gudlavalleti, Global Head of Integrated Product Development Organization
YUGANDHAR PUVVALA, Global Head of Supply Chain
Amit Biswas, Executive Vice President - Integrated Product Development
Ravi Bhoothalingam, Non-Executive Independent Director
Alok Sonig, Senior Vice President & India Business Head (Generics)
Allan Oberman, Non-Executive Independent Director
J Ramachandran, Executive Vice President-Management Systems and Corporate Initiatives
Prasad Menon, Lead Non-Executive Independent Director
K Rao, Sr. Vice President & Head ? Chemical Technical Operations (CTO)
Abhijit Mukherjee, COO
Anil Namboodiripad, Global Head of Proprietary Products
Saumen Chakraborty, President, Chief Financial Officer and Global Head of ITBPE, Legal and Compliance and FMCRE
SANJAY SHARMA, Global Head of Manufacturing
Shikha Sharma, Non-Executive Independent Director
Sridar Iyengar, Non-Executive Independent Director
Ganadhish Kamat, Executive Vice President and Global Head-Quality
Sripada Chandrasekhar, President, Global Head of HR and Member of Management Council
Omkar Goswami, Non-Executive Independent Director
Erez Israeli, Chief Operating Officer and Global Head of Generics & PSAI
Kalpana Morparia, Non-Executive Independent Director
Bharat Doshi, Non-Executive Independent Director
J Moreau, Non-Executive Independent Director
Raymond Vre, Global Head of Biologics
Raghav Chari, Senior Vice President - Proprietary Products
Bruce Carter, Non-Executive Independent Director
Saunak Savla, IR Contact Officer
Ashok Ganguly, Non-Executive Independent Director
Umang Vohra, Executive Vice President Head - North America Generics
M Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets)
Cartikeya Reddy, Senior Vice President Head - Biologics
Anupam Puri, Non-Executive Independent Director
Archana Bhaskar, Chief Human Resource Officer
Deepak Sapra, Global Head of PSAI

Stock Performance Indicators

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Currently Active Assets on Macroaxis

S   
Sold over 300 shares of
six days ago
Traded for 8.62
GM   
Sold over 100 shares of
six days ago
Traded for 25.24
XOM   
Sold over 60 shares of
six days ago
Traded for 44.08
OTPBF   
Sold over 100 shares of
six days ago
Traded for 28.82
MSFT   
Sold few shares of
six days ago
Traded for 206.26
Additionally, take a look at Your Equity Center. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page